HeartBeam Inc. (NASDAQ: BEAT) announced the issuance of a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its compact, cable-free ECG device. The patent expands the company's cardiac monitoring platform to support future applications in structural heart disease and heart failure, allowing the device to function as a digital stethoscope and assess fluid accumulation in the chest without altering its existing form factor.
The patent strengthens HeartBeam's intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications, and device hardware.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside a medical facility. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. For details on intended use, refer to the company’s Cleared Indications for Use at https://www.heartbeam.com/indications.
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. To view the full press release, visit https://ibn.fm/jgVf0.
